We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

35 hedge funds and large institutions have $211M invested in CRISPR Therapeutics in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

35% more funds holding

Funds holding: 26 → 35 (+9)

7% more capital invested

Capital invested by funds: $198M → $211M (+$13M)

0.41% less ownership

Funds ownership: 24.7% → 24.29% (-0.41%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
35
Holders Change
+9
Holders Change %
+34.62%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
18
Increased
5
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CS
Credit Suisse
Switzerland
+$1.57M
2
PC
Paulson & Co
New York
+$991K
3
Morgan Stanley
Morgan Stanley
New York
+$328K
4
Deutsche Bank
Deutsche Bank
Germany
+$135K
5
IWM
IHT Wealth Management
Illinois
+$109K

Top Sellers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$4.29M
2
JCG
JHL Capital Group
Illinois
-$1.22M
3
LCM
Laurion Capital Management
New York
-$527K
4
CCP
Clough Capital Partners
Massachusetts
-$273K
5
Millennium Management
Millennium Management
New York
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$70.1M – – –
A
2
Abingworth
United Kingdom
$56.6M – – –
CCP
3
Clough Capital Partners
Massachusetts
$17.9M -$273K -13,927 -2%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$16.3M +$60.3K +3,070 +0.4%
Franklin Resources
5
Franklin Resources
California
$15.7M – – –
NLVP
6
New Leaf Venture Partners
New York
$12.8M – – –
O
7
OrbiMed
New York
$8.1M – – –
NHAS
8
Novo Holdings A/S
Denmark
$4.86M – – –
VC
9
Vivo Capital
California
$3.24M – – –
CS
10
Credit Suisse
Switzerland
$1.74M +$1.57M +80,000 New
PC
11
Paulson & Co
New York
$1.1M +$991K +50,500 New
MIM
12
Monashee Investment Management
Massachusetts
$473K -$141K -7,186 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
$459K +$54.2K +2,760 +15%
Morgan Stanley
14
Morgan Stanley
New York
$447K +$328K +16,710 +438%
Bank of America
15
Bank of America
North Carolina
$316K -$137K -6,988 -33%
Deutsche Bank
16
Deutsche Bank
Germany
$150K +$135K +6,900 New
IWM
17
IHT Wealth Management
Illinois
$110K +$109K +5,547 New
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$74K +$66.3K +3,376 New
DSI
19
Daiwa SB Investments
Japan
$61K +$55K +2,800 New
TDC
20
Thompson Davis & Co
Virginia
$54K +$49.1K +2,500 New
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$36K +$32.2K +1,638 New
Wells Fargo
22
Wells Fargo
California
$31K +$8.78K +447 +46%
DBT
23
Dubuque Bank & Trust
Iowa
$31K +$28K +1,425 New
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$14.1K +$12.7K +648 New
LWCFA
25
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$13K – – –
1
2

CRSP Hedge Fund Activity: Q1 2017 in Review

35 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2017, worth a combined $211M — up 6.6% from $198M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CRSP positions and 9 closed out — a net gain of 9 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $1.57M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $4.29M sold.

  • 35 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2017, up from 26 in Q4 2016.
  • Funds reported $211M of CRISPR Therapeutics stock for Q1 2017, up 6.6% quarter-over-quarter.
  • 18 funds opened new CRISPR Therapeutics positions in Q1 2017 and 9 closed out, a net change of +9 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2017 was Credit Suisse, an estimated $1.57M added.
  • The largest CRISPR Therapeutics seller in Q1 2017 was Lord, Abbett & Co, an estimated $4.29M sold.

Based on aggregated 13F filings for Q1 2017.